Copyright Reports & Markets. All rights reserved.

Global Talacotuzumab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Talacotuzumab Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 10 mg / vial
    • 1.3.3 5 mg/mL
  • 1.4 Market Analysis by Dosage Form
    • 1.4.1 Overview: Global Talacotuzumab Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
    • 1.4.2 Lyophilized Powder
    • 1.4.3 Reconstituted Solution
  • 1.5 Market Analysis by Sales Channels
    • 1.5.1 Overview: Global Talacotuzumab Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
    • 1.5.2 Hospitals
    • 1.5.3 Retail
    • 1.5.4 Online
  • 1.6 Market Analysis by Application
    • 1.6.1 Overview: Global Talacotuzumab Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
    • 1.6.3 Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma
    • 1.6.4 Other CD19-Positive B-Cell Malignancies
    • 1.6.5 Others
  • 1.7 Global Talacotuzumab Market Size & Forecast
    • 1.7.1 Global Talacotuzumab Consumption Value (2021 & 2025 & 2032)
    • 1.7.2 Global Talacotuzumab Sales Quantity (2021-2032)
    • 1.7.3 Global Talacotuzumab Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 ADC Therapeutics SA（ADCT）
    • 2.1.1 ADC Therapeutics SA（ADCT） Details
    • 2.1.2 ADC Therapeutics SA（ADCT） Major Business
    • 2.1.3 ADC Therapeutics SA（ADCT） Talacotuzumab Product and Services
    • 2.1.4 ADC Therapeutics SA（ADCT） Talacotuzumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 ADC Therapeutics SA（ADCT） Recent Developments/Updates
  • 2.2 Overland Pharmaceuticals
    • 2.2.1 Overland Pharmaceuticals Details
    • 2.2.2 Overland Pharmaceuticals Major Business
    • 2.2.3 Overland Pharmaceuticals Talacotuzumab Product and Services
    • 2.2.4 Overland Pharmaceuticals Talacotuzumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Overland Pharmaceuticals Recent Developments/Updates
  • 2.3 Overland ADCT BioPharma (Shanghai)
    • 2.3.1 Overland ADCT BioPharma (Shanghai) Details
    • 2.3.2 Overland ADCT BioPharma (Shanghai) Major Business
    • 2.3.3 Overland ADCT BioPharma (Shanghai) Talacotuzumab Product and Services
    • 2.3.4 Overland ADCT BioPharma (Shanghai) Talacotuzumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Overland ADCT BioPharma (Shanghai) Recent Developments/Updates

3 Competitive Environment: Talacotuzumab by Manufacturer

  • 3.1 Global Talacotuzumab Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Talacotuzumab Revenue by Manufacturer (2021-2026)
  • 3.3 Global Talacotuzumab Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Talacotuzumab by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Talacotuzumab Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Talacotuzumab Manufacturer Market Share in 2025
  • 3.5 Talacotuzumab Market: Overall Company Footprint Analysis
    • 3.5.1 Talacotuzumab Market: Region Footprint
    • 3.5.2 Talacotuzumab Market: Company Product Type Footprint
    • 3.5.3 Talacotuzumab Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Talacotuzumab Market Size by Region
    • 4.1.1 Global Talacotuzumab Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Talacotuzumab Consumption Value by Region (2021-2032)
    • 4.1.3 Global Talacotuzumab Average Price by Region (2021-2032)
  • 4.2 North America Talacotuzumab Consumption Value (2021-2032)
  • 4.3 Europe Talacotuzumab Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Talacotuzumab Consumption Value (2021-2032)
  • 4.5 South America Talacotuzumab Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Talacotuzumab Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Talacotuzumab Sales Quantity by Type (2021-2032)
  • 5.2 Global Talacotuzumab Consumption Value by Type (2021-2032)
  • 5.3 Global Talacotuzumab Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Talacotuzumab Sales Quantity by Application (2021-2032)
  • 6.2 Global Talacotuzumab Consumption Value by Application (2021-2032)
  • 6.3 Global Talacotuzumab Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Talacotuzumab Sales Quantity by Type (2021-2032)
  • 7.2 North America Talacotuzumab Sales Quantity by Application (2021-2032)
  • 7.3 North America Talacotuzumab Market Size by Country
    • 7.3.1 North America Talacotuzumab Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Talacotuzumab Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Talacotuzumab Sales Quantity by Type (2021-2032)
  • 8.2 Europe Talacotuzumab Sales Quantity by Application (2021-2032)
  • 8.3 Europe Talacotuzumab Market Size by Country
    • 8.3.1 Europe Talacotuzumab Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Talacotuzumab Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Talacotuzumab Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Talacotuzumab Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Talacotuzumab Market Size by Region
    • 9.3.1 Asia-Pacific Talacotuzumab Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Talacotuzumab Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Talacotuzumab Sales Quantity by Type (2021-2032)
  • 10.2 South America Talacotuzumab Sales Quantity by Application (2021-2032)
  • 10.3 South America Talacotuzumab Market Size by Country
    • 10.3.1 South America Talacotuzumab Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Talacotuzumab Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Talacotuzumab Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Talacotuzumab Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Talacotuzumab Market Size by Country
    • 11.3.1 Middle East & Africa Talacotuzumab Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Talacotuzumab Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Talacotuzumab Market Drivers
  • 12.2 Talacotuzumab Market Restraints
  • 12.3 Talacotuzumab Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Talacotuzumab and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Talacotuzumab
  • 13.3 Talacotuzumab Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Talacotuzumab Typical Distributors
  • 14.3 Talacotuzumab Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Talacotuzumab market size was valued at US$ 75.11 million in 2025 and is forecast to a readjusted size of US$ 117 million by 2032 with a CAGR of 4.8% during review period.
    Loncastuximab tesirine (trade name Zynlonta) is a humanized CD19-targeted antibody-drug conjugate (ADC). It consists of a CD19-targeted monoclonal antibody, a cleavable linker, and a pyrrolobenzodiazepine (PBD) dimer toxin. It is mainly indicated for the treatment of CD19-positive B-cell malignancies such as relapsed or refractory diffuse large B-cell lymphoma. Its mechanism of action involves the specific binding of the antibody to the CD19 antigen on the surface of tumor cells, followed by internalization into the cells and release of the toxin. The toxin induces interstrand DNA crosslinks to block DNA replication and transcription, thereby killing tumor cells. Featuring high targeting specificity and potent antitumor activity, it provides an important therapeutic option for lymphoma patients who have received multiple prior lines of therapy.In 2025, global Loncastuximab production reached approximately 7,360 vials
    As one of the first CD19-targeted antibody-drug conjugates launched globally, loncastuximab tesirine holds an important position in the field of relapsed and refractory lymphoma due to its unique PBD toxin mechanism and precise targeting. However, its overall market size is constrained by its current approved indications. With a steady commercialization process, it mainly targets a niche patient population receiving later-line therapy, showing moderate market growth and focusing on consolidating its existing therapeutic position in the short term. In the competitive landscape, the drug faces intense pressure from CD19-targeted CAR-T therapies, bispecific antibodies, and similar ADCs, with its differentiated advantages lying in convenient administration and accessibility. Its long-term growth potential highly depends on the expansion to second-line and frontline indications, the development of combination therapies, and global market penetration. If key clinical progress proceeds smoothly, it is expected to break through current market constraints and further expand its share in targeted therapies for B-cell lymphoma.
    This report is a detailed and comprehensive analysis for global Talacotuzumab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Talacotuzumab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Talacotuzumab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Talacotuzumab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Talacotuzumab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Talacotuzumab
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Talacotuzumab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ADC Therapeutics SA（ADCT）, Overland Pharmaceuticals, Overland ADCT BioPharma (Shanghai), etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Talacotuzumab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    10 mg / vial
    5 mg/mL
    Market segment by Dosage Form
    Lyophilized Powder
    Reconstituted Solution
    Market segment by Sales Channels
    Hospitals
    Retail
    Online
    Market segment by Application
    Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
    Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma
    Other CD19-Positive B-Cell Malignancies
    Others
    Major players covered
    ADC Therapeutics SA（ADCT）
    Overland Pharmaceuticals
    Overland ADCT BioPharma (Shanghai)
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Talacotuzumab product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Talacotuzumab, with price, sales quantity, revenue, and global market share of Talacotuzumab from 2021 to 2026.
    Chapter 3, the Talacotuzumab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Talacotuzumab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Talacotuzumab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Talacotuzumab.
    Chapter 14 and 15, to describe Talacotuzumab sales channel, distributors, customers, research findings and conclusion.

    Buy now